NO322016B1 - Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser - Google Patents

Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser Download PDF

Info

Publication number
NO322016B1
NO322016B1 NO20015547A NO20015547A NO322016B1 NO 322016 B1 NO322016 B1 NO 322016B1 NO 20015547 A NO20015547 A NO 20015547A NO 20015547 A NO20015547 A NO 20015547A NO 322016 B1 NO322016 B1 NO 322016B1
Authority
NO
Norway
Prior art keywords
group
compound
formula
ring
saframycin
Prior art date
Application number
NO20015547A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015547D0 (no
NO20015547L (no
Inventor
Carmen Cuevas
Andres Francesch
Carolina Fernandez
Jose Luis Chicharro
Pilar Gallego
Maria Zarzuelo
Fernando De La Calle
Ignacio Manzanares
Marta Perez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911345.8A external-priority patent/GB9911345D0/en
Priority claimed from GBGB9918178.6A external-priority patent/GB9918178D0/en
Priority claimed from GBGB9923632.5A external-priority patent/GB9923632D0/en
Priority claimed from GB0001063A external-priority patent/GB0001063D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20015547D0 publication Critical patent/NO20015547D0/no
Publication of NO20015547L publication Critical patent/NO20015547L/no
Publication of NO322016B1 publication Critical patent/NO322016B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
NO20015547A 1999-05-14 2001-11-13 Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser NO322016B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9911345.8A GB9911345D0 (de) 1999-05-14 1999-05-14
GBGB9918178.6A GB9918178D0 (en) 2000-05-15 1999-08-02 Synthetic methods
GBGB9923632.5A GB9923632D0 (en) 1999-10-06 1999-10-06 Hemisynthetic process towards ecteinascidin and phtalscidin compounds
GB0001063A GB0001063D0 (en) 2000-01-17 2000-01-17 Hemisynthetic process towards ecteinascidin and phtalascidin
PCT/GB2000/001852 WO2000069862A2 (en) 1999-05-14 2000-05-15 Hemisynthetic method and intermediates thereof

Publications (3)

Publication Number Publication Date
NO20015547D0 NO20015547D0 (no) 2001-11-13
NO20015547L NO20015547L (no) 2002-01-14
NO322016B1 true NO322016B1 (no) 2006-08-07

Family

ID=42632476

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20015547A NO322016B1 (no) 1999-05-14 2001-11-13 Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser
NO20025186A NO328301B1 (no) 1999-05-14 2002-10-29 Fremgangsmate for syntese av en ecteinascidinforbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20025186A NO328301B1 (no) 1999-05-14 2002-10-29 Fremgangsmate for syntese av en ecteinascidinforbindelse

Country Status (30)

Country Link
US (3) US7241892B1 (de)
EP (1) EP1185536B1 (de)
JP (1) JP4445136B2 (de)
KR (1) KR100834601B1 (de)
CN (3) CN1229382C (de)
AR (1) AR035842A1 (de)
AT (1) ATE283273T1 (de)
AU (2) AU775580B2 (de)
BG (1) BG65896B1 (de)
BR (3) BRPI0010559B8 (de)
CA (2) CA2372058C (de)
CY (1) CY1108095T1 (de)
CZ (3) CZ303536B6 (de)
DE (1) DE60016209T2 (de)
DK (1) DK1185536T3 (de)
ES (2) ES2233367T3 (de)
HK (1) HK1047432A1 (de)
HU (1) HU230646B1 (de)
MX (1) MXPA01011631A (de)
MY (1) MY130271A (de)
NO (2) NO322016B1 (de)
NZ (1) NZ515424A (de)
PL (1) PL226890B1 (de)
PT (1) PT1185536E (de)
RU (1) RU2237063C9 (de)
SI (2) SI1185536T1 (de)
SK (2) SK287835B6 (de)
TR (1) TR200103273T2 (de)
UA (1) UA75333C2 (de)
WO (3) WO2000069862A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239442T3 (es) 1998-05-11 2005-09-16 Pharma Mar, S.A. Metabolitos de ecteinascidina 743.
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
NZ521808A (en) * 2000-05-15 2004-07-30 Pharma Mar S Synthetic process for the manufacture of an ecteinaschidin compound
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US6809099B2 (en) 2000-11-03 2004-10-26 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
CZ20031327A3 (cs) * 2000-11-06 2003-11-12 Pharma Mar, S. A. Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
CA2462502A1 (en) * 2001-10-19 2003-05-15 Pharma Mar, S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7183054B2 (en) 2003-06-03 2007-02-27 President And Fellows Of Harvard College Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et-743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CN101068596A (zh) * 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
SI1827500T1 (sl) * 2004-10-26 2009-10-31 Pharma Mar Sa Pegiliran liposomski doksorubicin v kombinaciji s ekteinescidinom 743
SI1658848T1 (sl) 2004-10-29 2007-12-31 Pharma Mar Sa Formulacije vsebujoäśe ekteinascidin in disaharid
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR100712667B1 (ko) 2006-04-11 2007-05-02 재단법인서울대학교산학협력재단 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
JP2011520921A (ja) * 2008-05-16 2011-07-21 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍アルカロイドとの併用療法
KR20110028454A (ko) * 2008-05-16 2011-03-18 파르마 마르 에스.에이. 다발성 골수종 치료법
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
US9428524B2 (en) 2010-05-25 2016-08-30 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
RS54648B1 (en) 2010-11-12 2016-08-31 Pharma Mar S.A. COMBINED THERAPY WITH ANTITUMOR ALKALOID
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN107739387B (zh) * 2017-10-16 2020-01-03 上海皓元生物医药科技有限公司 一种制备曲贝替定的关键中间体化合物的方法
CN109912629B (zh) * 2017-12-13 2021-12-24 浙江中科创越药业有限公司 天然产物Trabectedin的制备
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN111518110B (zh) * 2019-02-01 2023-11-03 博瑞生物医药(苏州)股份有限公司 一种海鞘素化合物及其中间体的制备方法
CN111620792B (zh) * 2019-02-28 2023-01-03 兰州大学 一种n,n-二取代氰基甲酰胺的合成方法
CN116217584A (zh) * 2021-12-06 2023-06-06 南通诺泰生物医药技术有限公司 Et743及其中间体的光催化合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6054386A (ja) * 1983-09-02 1985-03-28 Yoshitomi Pharmaceut Ind Ltd サフラシン誘導体
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン729、743、745、759a、759bおよび770
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6124293A (en) 1998-04-06 2000-09-26 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
ES2239442T3 (es) 1998-05-11 2005-09-16 Pharma Mar, S.A. Metabolitos de ecteinascidina 743.
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
CA2397597A1 (en) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
SK15272002A3 (sk) 2003-06-03
BRPI0110443B8 (pt) 2021-05-25
AU775580B2 (en) 2004-08-05
SK16502001A3 (sk) 2002-06-04
AR035842A1 (es) 2004-07-21
CN1440414A (zh) 2003-09-03
CZ303536B6 (cs) 2012-11-21
TR200103273T2 (tr) 2002-04-22
HU230646B1 (hu) 2017-05-29
CZ20014102A3 (cs) 2002-06-12
CN1441805A (zh) 2003-09-10
BG107301A (bg) 2003-07-31
US20040002602A1 (en) 2004-01-01
RU2237063C9 (ru) 2008-10-10
BR0010559A (pt) 2002-07-02
DE60016209D1 (de) 2004-12-30
WO2000069862A3 (en) 2001-03-22
CZ20023746A3 (cs) 2003-04-16
WO2001087895A1 (en) 2001-11-22
CA2406095C (en) 2010-02-16
NO20015547D0 (no) 2001-11-13
CN100475822C (zh) 2009-04-08
DE60016209T2 (de) 2005-12-15
CY1108095T1 (el) 2014-02-12
WO2000069862A2 (en) 2000-11-23
SK287835B6 (sk) 2011-12-05
EP1185536A2 (de) 2002-03-13
WO2001087894A1 (en) 2001-11-22
UA75333C2 (uk) 2006-04-17
BRPI0110801B1 (pt) 2018-02-27
ES2231486T3 (es) 2005-05-16
US7241892B1 (en) 2007-07-10
CZ20023751A3 (en) 2004-05-12
PL353002A1 (en) 2003-09-22
AU5649601A (en) 2001-11-26
BRPI0010559B8 (pt) 2021-05-25
PT1185536E (pt) 2005-04-29
SI1185536T1 (en) 2005-06-30
EP1185536B1 (de) 2004-11-24
ATE283273T1 (de) 2004-12-15
MXPA01011631A (es) 2002-07-30
BR0110801A (pt) 2003-02-11
MY130271A (en) 2007-06-29
HUP0201188A2 (en) 2002-07-29
PL226890B1 (pl) 2017-09-29
CN1211386C (zh) 2005-07-20
CA2372058C (en) 2010-10-26
ES2233367T3 (es) 2005-06-16
US20080045713A1 (en) 2008-02-21
NO20015547L (no) 2002-01-14
JP2002544280A (ja) 2002-12-24
DK1185536T3 (da) 2005-04-04
KR20020021636A (ko) 2002-03-21
SI1287004T1 (sl) 2005-12-31
HK1047432A1 (en) 2003-02-21
CN1229382C (zh) 2005-11-30
US7524956B2 (en) 2009-04-28
NO328301B1 (no) 2010-01-25
CA2372058A1 (en) 2000-11-23
CN1360588A (zh) 2002-07-24
BRPI0110443B1 (pt) 2018-06-26
CZ304966B6 (cs) 2015-02-18
BG65896B1 (bg) 2010-04-30
CZ304973B6 (cs) 2015-02-25
NZ515424A (en) 2004-06-25
NO20025186L (no) 2003-01-14
CA2406095A1 (en) 2001-11-22
SK287879B6 (sk) 2012-02-03
KR100834601B1 (ko) 2008-06-02
BRPI0110801B8 (pt) 2021-05-25
NO20025186D0 (no) 2002-10-29
AU4597300A (en) 2000-12-05
RU2237063C2 (ru) 2004-09-27
JP4445136B2 (ja) 2010-04-07
BRPI0010559B1 (pt) 2016-08-30
BR0110443A (pt) 2003-04-08

Similar Documents

Publication Publication Date Title
NO322016B1 (no) Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser
US7420051B2 (en) Synthetic process for the manufacture of an ecteinaschidin compound
EP1287004B1 (de) Synthetisches verfahren zur herstellung von ecteinascidin-derivaten
AU2001256496A1 (en) Synthetic process for the manufacture of an ecteinascidin compound
NO329561B1 (no) Forbindelser som er analoger av ET-743, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene til fremstilling av farmasoytiske preparater for anvendelse ved behandling av tumorer
BG106216A (bg) Полусинтетичен метод и нови съединения
NZ521808A (en) Synthetic process for the manufacture of an ecteinaschidin compound

Legal Events

Date Code Title Description
MK1K Patent expired